title: Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment.
abstract: Accumulating evidence implicates the growth hormone receptor (GHR) in carcinogenesis. While multiple studies show evidence for expression of growth hormone (GH) and GHR mRNA in human cancer tissue, there is a lack of quantification and only a few cancer types have been investigated. The National Cancer Institute's NCI60 panel includes 60 cancer cell lines from nine types of human cancer: breast, CNS, colon, leukemia, melanoma, non-small cell lung, ovarian, prostate and renal. We utilized this panel to quantify expression of GHR, GH, prolactin receptor (PRLR) and prolactin (PRL) mRNA with real-time RT qPCR. Both GHR and PRLR show a broad range of expression within and among most cancer types. Strikingly, GHR expression is nearly 50-fold higher in melanoma than in the panel as a whole. Analysis of human metastatic melanoma biopsies confirmed GHR gene expression in melanoma tissue. In these human biopsies, the level of GHR mRNA is elevated in advanced stage IV tumor samples compared to stage III. Due to the novel finding of high GHR in melanoma, we examined the effect of GH treatment on three NCI60 melanoma lines (MDA-MB-435, UACC-62 and SK-MEL-5). GH increased proliferation in two out of three cell lines tested. Further analysis revealed GH-induced activation of STAT5 and mTOR in a cell line dependent manner. In conclusion, we have identified cell lines and cancer types that are ideal to study the role of GH and PRL in cancer, yet have been largely overlooked. Furthermore, we found that human metastatic melanoma tumors express GHR and cell lines possess active GHRs that can modulate multiple signaling pathways and alter cell proliferation. Based on this data, GH could be a new therapeutic target in melanoma.
authors.affiliation: Edison Biotechnology Institute, 1 Watertower Drive, Athens, OH, United States; Department of Biological Sciences, Ohio University, Athens, OH, United States.
authors.forename: Elahu G
authors.initials: EG
authors.lastname: Sustarsic
authors.forename: Riia K
authors.initials: RK
authors.lastname: Junnila
authors.forename: John J
authors.initials: JJ
authors.lastname: Kopchick
mesh_terms: D001706:Biopsy; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D030541:Databases, Genetic; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D013006:Growth Hormone / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008545:Melanoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011986:Receptors, Somatotropin / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics
chemical_list: D012333:RNA, Messenger; D011986:Receptors, Somatotropin; D013006:Growth Hormone
keywords: Cancer; Growth hormone; Growth hormone receptor; Melanoma; Prolactin receptor